Lista de obras - Timothy P Hickling - Dominio Público Uruguay

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

scientific article published on 08 October 2019

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

scientific article published on 30 August 2013

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

artículo científico publicado en 2014

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications

artículo científico publicado en 2014

A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo

artículo científico publicado en 1999

A review of quantitative modeling of B cell responses to antigenic challenge.

artículo científico publicado en 2014

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets

artículo científico publicado en 2005

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

artículo científico publicado en 2008

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies

artículo científico publicado en 2015

CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.

artículo científico publicado en 2013

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

artículo científico publicado en 2006

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

artículo científico publicado en 2007

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

artículo científico publicado en 2006

Induction of TNF-alpha release from human buffy coat cells by Pseudomonas aeruginosa is reduced by lung surfactant protein A

scientific article published on 01 October 1998

Mannan binding lectin and viral hepatitis

artículo científico publicado en 2006

Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.

artículo científico publicado en 2012

Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

artículo científico publicado en 2014

Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex

artículo científico publicado en 2007

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

artículo científico publicado en 2010

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

artículo científico publicado en 2013

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

artículo científico

Lista de obras de Timothy P Hickling

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications

A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo

A review of quantitative modeling of B cell responses to antigenic challenge.

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies

CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

Induction of TNF-alpha release from human buffy coat cells by Pseudomonas aeruginosa is reduced by lung surfactant protein A

Mannan binding lectin and viral hepatitis

Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.

Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.